These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
381 related articles for article (PubMed ID: 31667638)
1. Characterization of Phase Transformations for Amorphous Solid Dispersions of a Weakly Basic Drug upon Dissolution in Biorelevant Media. Elkhabaz A; Sarkar S; Simpson GJ; Taylor LS Pharm Res; 2019 Oct; 36(12):174. PubMed ID: 31667638 [TBL] [Abstract][Full Text] [Related]
2. Phase Behavior of Ritonavir Amorphous Solid Dispersions during Hydration and Dissolution. Purohit HS; Taylor LS Pharm Res; 2017 Dec; 34(12):2842-2861. PubMed ID: 28956218 [TBL] [Abstract][Full Text] [Related]
3. Variation in Supersaturation and Phase Behavior of Ezetimibe Amorphous Solid Dispersions upon Dissolution in Different Biorelevant Media. Elkhabaz A; Sarkar S; Dinh JK; Simpson GJ; Taylor LS Mol Pharm; 2018 Jan; 15(1):193-206. PubMed ID: 29161509 [TBL] [Abstract][Full Text] [Related]
4. Combined Effects of Supersaturation Rates and Doses on the Kinetic-Solubility Profiles of Amorphous Solid Dispersions Based on Water-Insoluble Poly(2-hydroxyethyl methacrylate) Hydrogels. Schver GCRM; Lee PI Mol Pharm; 2018 May; 15(5):2017-2026. PubMed ID: 29601723 [TBL] [Abstract][Full Text] [Related]
5. Enhanced kinetic solubility profiles of indomethacin amorphous solid dispersions in poly(2-hydroxyethyl methacrylate) hydrogels. Sun DD; Ju TC; Lee PI Eur J Pharm Biopharm; 2012 May; 81(1):149-58. PubMed ID: 22233548 [TBL] [Abstract][Full Text] [Related]
6. Amorphous Solid Dispersion Formation for Enhanced Release Performance of Racemic and Enantiopure Praziquantel. Polyzois H; Nguyen HT; Roberto de Alvarenga Junior B; Taylor LS Mol Pharm; 2024 Oct; 21(10):5285-5296. PubMed ID: 39292641 [TBL] [Abstract][Full Text] [Related]
7. Drug Release and Nanodroplet Formation from Amorphous Solid Dispersions: Insight into the Roles of Drug Physicochemical Properties and Polymer Selection. Yang R; Mann AKP; Van Duong T; Ormes JD; Okoh GA; Hermans A; Taylor LS Mol Pharm; 2021 May; 18(5):2066-2081. PubMed ID: 33784104 [TBL] [Abstract][Full Text] [Related]
8. Improved Release of Celecoxib from High Drug Loading Amorphous Solid Dispersions Formulated with Polyacrylic Acid and Cellulose Derivatives. Xie T; Taylor LS Mol Pharm; 2016 Mar; 13(3):873-84. PubMed ID: 26791934 [TBL] [Abstract][Full Text] [Related]
9. Probing the mechanisms of drug release from amorphous solid dispersions in medium-soluble and medium-insoluble carriers. Sun DD; Lee PI J Control Release; 2015 Aug; 211():85-93. PubMed ID: 26054795 [TBL] [Abstract][Full Text] [Related]
10. Congruent Release of Drug and Polymer from Amorphous Solid Dispersions: Insights into the Role of Drug-Polymer Hydrogen Bonding, Surface Crystallization, and Glass Transition. Saboo S; Kestur US; Flaherty DP; Taylor LS Mol Pharm; 2020 Apr; 17(4):1261-1275. PubMed ID: 32134677 [TBL] [Abstract][Full Text] [Related]
11. Dissolution of Danazol Amorphous Solid Dispersions: Supersaturation and Phase Behavior as a Function of Drug Loading and Polymer Type. Jackson MJ; Kestur US; Hussain MA; Taylor LS Mol Pharm; 2016 Jan; 13(1):223-31. PubMed ID: 26618718 [TBL] [Abstract][Full Text] [Related]
12. Insights into the Dissolution Mechanism of Ritonavir-Copovidone Amorphous Solid Dispersions: Importance of Congruent Release for Enhanced Performance. Indulkar AS; Lou X; Zhang GGZ; Taylor LS Mol Pharm; 2019 Mar; 16(3):1327-1339. PubMed ID: 30669846 [TBL] [Abstract][Full Text] [Related]
13. Insights into the Release Mechanisms of ITZ:HPMCAS Amorphous Solid Dispersions: The Role of Drug-Rich Colloids. Nunes PD; Pinto JF; Henriques J; Paiva AM Mol Pharm; 2022 Jan; 19(1):51-66. PubMed ID: 34919407 [TBL] [Abstract][Full Text] [Related]
14. Influence of Particle Size and Drug Load on Amorphous Solid Dispersions Containing pH-Dependent Soluble Polymers and the Weak Base Ketoconazole. Monschke M; Kayser K; Wagner KG AAPS PharmSciTech; 2021 Jan; 22(1):44. PubMed ID: 33438107 [TBL] [Abstract][Full Text] [Related]
15. Jermain SV; Lowinger MB; Ellenberger DJ; Miller DA; Su Y; Williams RO Mol Pharm; 2020 Aug; 17(8):2789-2808. PubMed ID: 32520562 [TBL] [Abstract][Full Text] [Related]
16. Dissolution Behavior of Weakly Basic Pharmaceuticals from Amorphous Dispersions Stabilized by a Poly(dimethylaminoethyl Methacrylate) Copolymer. Frank DS; Prasad P; Iuzzolino L; Schenck L Mol Pharm; 2022 Sep; 19(9):3304-3313. PubMed ID: 35985017 [TBL] [Abstract][Full Text] [Related]
17. Dissolution and precipitation behavior of amorphous solid dispersions. Alonzo DE; Gao Y; Zhou D; Mo H; Zhang GGZ; Taylor LS J Pharm Sci; 2011 Aug; 100(8):3316-3331. PubMed ID: 21607951 [TBL] [Abstract][Full Text] [Related]
18. Fed- and Fasted-State Performance of Pretomanid Amorphous Solid Dispersions Formulated with an Enteric Polymer. Nguyen HT; Van Duong T; Jaw-Tsai S; Bruning-Barry R; Pande P; Taneja R; Taylor LS Mol Pharm; 2023 Jun; 20(6):3170-3186. PubMed ID: 37220082 [TBL] [Abstract][Full Text] [Related]
19. Dissolution performance of binary amorphous drug combinations--Impact of a second drug on the maximum achievable supersaturation. Trasi NS; Taylor LS Int J Pharm; 2015 Dec; 496(2):282-90. PubMed ID: 26456250 [TBL] [Abstract][Full Text] [Related]
20. A high-sensitivity HPLC-ELSD method for HPMC-AS quantification and its application in elucidating the release mechanism of HPMC-AS based amorphous solid dispersions. Wang S; Liu C; Chen Y; Zhang Z; Zhu A; Qian F Eur J Pharm Sci; 2018 Sep; 122():303-310. PubMed ID: 30006181 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]